ArticleCells2022
Skeletal Muscle Pathological Fat Infiltration (Myosteatosis) Is Associated with Higher Mortality in Patients with Cirrhosis.
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06593015 (Study Protocol to Redefine Muscle Attenuation Cut-offs for Better Prediction of Mortality in Patients With Cirrhosis), which is not on this map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study Protocol to Redefine Muscle Attenuation Cut-offs for Better Prediction of Mortality in Patients With Cirrhosis: a Comprehensive Post-hoc Validation Study
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis.Hepatology international · 2024Pooled it
- Myosteatosis and the clinical outcomes of patients with liver cirrhosis: A meta-analysis.PloS one · 2024Pooled it
- Prognostic impact of myosteatosis in patients with colorectal cancer undergoing curative surgery: an updated systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.United European gastroenterology journal · 2022Guideline
- Myosteatosis as a prognostic biomarker for post-transplant survival and cardiometabolic outcomes: A retrospective study.Canadian liver journal · 2026Article
- Sarcopenia Predicts Mortality and Hepatic Encephalopathy After TIPS in Older Adults With Cirrhosis and Improves Prognostic Scores.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Investigating the Prognostic Value of Pretreatment Body Composition in Women with Ovarian Cancer: Impact on Clinical Outcomes.Cancers · 2026Article
- Myosteatosis mediates the link between specific dietary components and colorectal carcinogenesis: from PPLSS multi-center study.Asia Pacific journal of clinical nutrition · 2026Article
- Quality and Quantity? The Clinical Significance of Myosteatosis in Various Liver Diseases: A Narrative Review.Journal of clinical and translational hepatology · 2025Review
- Myosteatosis: Epidemiological Insights, Functional Decline, and Diagnostic Advances.Current obesity reports · 2025Review
- Sarcopenic obesity exacerbates gastric cancer prognosis via increased intermuscular and visceral fat accumulation.European journal of medical research · 2025Observational
- Reconsidering the urea-to-creatinine ratio as a signal of muscle catabolism in patients with cirrhosis.Critical care (London, England) · 2025Article
- Development of a deep learning model for predicting skeletal muscle density from ultrasound data: a proof-of-concept study.La Radiologia medica · 2025Article
- Type II fibre atrophy and nuclear disruption in decompensated cirrhosis.JHEP reports : innovation in hepatology · 2025Article
- Biomarkers and Clinical Evaluation in the Detection of Frailty.International journal of molecular sciences · 2025Review
- The Role of Muscle Density in Predicting the Amputation Risk in Peripheral Arterial Disease: A Tissue Composition Study Using Lower Extremity CT Angiography.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Correlation study on gut microbiota and myosteatosis in patients with liver cirrhosis.Frontiers in nutrition · 2025Article
- Validating the prognostic value of muscle changes in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt.Hepatobiliary surgery and nutrition · 2024Article
- Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma.Hepatology international · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Myosteatosis (pathological fat accumulation in muscle) is defined by lower mean skeletal muscle radiodensity in CT. We aimed to determine the optimal cut-offs for myosteatosis in a cohort of 855 patients with cirrhosis. CT images were used to determine the skeletal muscle radiodensity expressed as Hounsfield Unit (HU). Patients with muscle radiodensity values below the lowest tertile were considered to have myosteatosis. Competing-risk analysis was performed to determine associations between muscle radiodensity and pre-transplant mortality. Muscle radiodensity less than 33 and 28 HU in males and females, respectively, were used as cut-offs to identify myosteatosis. In the univariate analysis, cirrhosis etiology, MELD score, refractory ascites, variceal bleeding, hepatic encephalopathy, sarcopenia and myosteatosis were predictors of mortality. Myosteatosis association with mortality remained significant after adjusting for confounding factors (sHR 1.47, 95% CI 1.17−1.84, p = 0.001). Patients with concurrent presence of myosteatosis and sarcopenia constituted 17% of the patient population. The cumulative incidence of mortality was the highest in patients with concomitant sarcopenia and myosteatosis (sHR 2.22, 95% CI 1.64−3.00, p < 0.001). In conclusion, myosteatosis is common in patients with cirrhosis and is associated with increased mortality. The concomitant presence of myosteatosis and sarcopenia is associated with worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.